Total amount raised
$529 Millions
Latest funding date
03/01/2024
Location
Alumis has successfully closed a Series C funding round, attracting investments from 12 investors, including Samsara BioCapital and HBM Healthcare Investments. The company is dedicated to pioneering precision therapies for autoimmune disorders.
Keep reading to explore the intricacies of Alumis' fundraising journey and the investors backing this innovative platform.
What Is Alumis?
Alumis, founded in 2021, is a biotechnology company based in San Francisco, California. The company operates in the biotechnology, healthcare, life science, and precision medicine industries.
Founded by June Lee, Alumis employs 11-50 people and focuses on developing precision therapies for autoimmune disorders. The company leverages its analytics platform to create treatments aimed at improving the quality of life for patients with immune-mediated diseases.
How Much Funding Has Alumis Raised?
- Series A
- Amount Raised: $70M
- Date: May 2021
- Lead Investors: Foresite Capital
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To establish the company and initiate the development of precision therapies for autoimmune disorders.
- Series B
- Amount Raised: $200M
- Date: January 2022
- Lead Investors: Matrix Capital Management
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand research and development efforts and advance clinical trials for their lead candidates.
- Series C
- Amount Raised: $259M
- Date: March 2024
- Lead Investors: Foresite Capital, Samsara BioCapital, venBio Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the advancement of their precision data analytics and multi-platform approach, and to explore additional autoimmune indications.
Total Amount Raised: $529M. Current Valuation: Not publicly disclosed.
Key Investors
- Foresite Capital
- Details: Foresite Capital is a healthcare and life sciences investment firm. They have been a significant investor in Alumis, leading the Series C funding round.
- Investment Focus Areas: Healthcare, Life sciences, Biotechnology
- Notable Investments: 10x Genomics, Relay Therapeutics
- Samsara BioCapital
- Details: Samsara BioCapital is a venture capital firm focused on early-stage life sciences companies. They joined Alumis as a new investor in the Series C round.
- Investment Focus Areas: Biotechnology, Pharmaceuticals, Healthcare
- Notable Investments: Allakos, Principia Biopharma
- venBio Partners
- Details: venBio Partners is a life sciences investment firm. They participated as a new investor in Alumis' Series C funding round.
- Investment Focus Areas: Biotechnology, Pharmaceuticals, Medical devices
- Notable Investments: Arvinas, Mirati Therapeutics
- Matrix Capital Management
- Details: Matrix Capital Management is an investment management firm. They led the Series B funding round for Alumis.
- Investment Focus Areas: Technology, Healthcare, Consumer
- Notable Investments: Not publicly disclosed
- HBM Healthcare Investments
- Details: HBM Healthcare Investments is a firm that invests in healthcare and biotechnology companies. They joined Alumis as a new investor in the Series C round.
- Investment Focus Areas: Healthcare, Biotechnology
- Notable Investments: Harmony Biosciences, Argenx
What's Next for Alumis?
Alumis stands at the cusp of significant opportunities with its lead candidate, ESK-001, targeting conditions like plaque psoriasis and systemic lupus erythematosus. The company is also advancing A-005 for neuroinflammatory diseases, with clinical trials set to begin soon. These developments could open substantial market opportunities, bolstered by the recent $259 million Series C funding.
Future fundraising seems promising as Alumis progresses through clinical trials and expands its pipeline. However, challenges such as clinical trial risks and regulatory hurdles remain. The competitive landscape in biopharmaceuticals also poses potential obstacles. Yet, with a strong focus on precision medicine, Alumis is well-positioned for growth.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Alumis and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
